RxDoctor Payments DataLook up a doctor →

Courtney Ackerman, MD

Hematology & Oncology · Silver Spring, MDNPI 1790919744

Payments from drug & device makers

$1,253,962in general payments, 2019–2025

Across 1,083 payments — averaging $1157.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1.2M
  • Genentech, Inc.$26K
  • Novartis$5K
  • Johnson & Johnson$2K
  • Pfizer$838
  • Merck$758
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)83$1,204,495
Genentech, Inc.8$26,150
Novartis125$5,208
Johnson & Johnson(2 entities)82$1,754
Pfizer53$838
Merck45$758
E.r. Squibb & Sons, L.L.C.36$679
Sanofi32$673
Genentech USA, Inc.37$669
Eisai Inc.35$659
GSK25$647
Daiichi Sankyo Inc.24$580
AbbVie19$552
Seagen Inc.27$529
Bristol Myers Squibb26$523
Incyte Corporation24$494
Takeda Pharmaceuticals U.S.A., Inc.22$444
Amgen25$434
Regeneron Healthcare Solutions, Inc.17$349
Pharmacyclics LLC, An Abbvie Company15$321
Bayer14$316
AVEO Pharmaceuticals, Inc.9$315
Lilly USA, LLC16$284
Pharmaessentia USA Corporation11$273
Astellas Pharma US Inc12$268
Gilead(2 entities)11$250
Rigel Pharmaceuticals, Inc.12$242
Dendreon Pharmaceuticals LLC9$228
Exelixis Inc.10$227
Octapharma USA, Inc.1$210
Ipsen Biopharmaceuticals, Inc10$200
Taiho Oncology, Inc.9$198
Puma Biotechnology, Inc.11$198
Global Blood Therapeutics, Inc.11$180
EMD Serono, Inc.7$170
Tersera Therapeutics LLC6$167
ADC Therapeutics America, Inc.7$165
Pharmacosmos Therapeutics Inc.7$161
Boehringer Ingelheim8$161
Karyopharm Therapeutics Inc.7$154
Array Biopharma Inc7$152
Servier Pharmaceuticals LLC8$144
Beigene USA, Inc.5$143
Mirati Therapeutics, Inc.4$140
Genmab U.S., Inc.4$136
Sobi, Inc7$136
G1 Therapeutics, Inc.5$117
Agios Pharmaceuticals, Inc.5$108
Blueprint Medicines Corporation5$99
Stemline Therapeutics Inc.5$94
Adaptive Biotechnologies Corporation4$91
Tactile Systems Technology Inc6$86
Deciphera Pharmaceuticals Inc.5$83
Morphosys, US Inc.4$80
Foundation Medicine, Inc.4$76
Sumitomo Pharma America, Inc.4$75
Boston Scientific3$74
Clovis Oncology, Inc.4$73
EUSA Pharma (US) LLC3$64
Kyowa Kirin, Inc.3$60

How this compares

$1,253,962 in reported general payments places this provider in the 85th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$3,500,313
Medicare patients
719
Services billed
209,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Silver Spring

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →